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BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors
for the treatment of cancer, but it interferes as an off-target effect with microtubule
polymerization. Here, we developed two chemical derivatives that differ from BKM120 by
only one atom. We show that these minute changes separate the dual activity of BKM120 into
discrete PI3K and tubulin inhibitors. Analysis of the compounds cellular growth arrest
phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is
mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.
Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide
insights into the selective mode of action of this class of drugs. Our results raise concerns
over BKM120’s generally accepted mode of action, and provide a unique mechanistic basis
for next-generation PI3K inhibitors with improved safety proﬁles and ﬂexibility for use in
combination therapies.
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P
hosphoinositide 3-kinases (PI3Ks) promote cell growth,
survival, division and motility, and signal through protein
kinase B (PKB/Akt) and the mammalian target of
rapamycin (mTOR) to control cellular growth and proliferation.
The PI3K/PKB/mTOR pathway is frequently upregulated in
a wide range of tumours, and is therefore considered a valuable
drug target in cancer therapy. Speciﬁc PI3K inhibitors typically
display a cytostatic action, and cause cell cycle arrest in the
G1/S phase1. To date, an impressive number of PI3K and mTOR
inhibitors targeting the ATP-binding pocket of PI3K and
PI3K-related kinases (PIKK) are in clinical trials2. Among
those, NVP-BKM120 (BKM120) is one of the clinically most
advanced pan-PI3K inhibitors, as it is enlisted in more than
80 clinical studies as a single drug or in combination therapies3–6.
In contrast to targeted therapy by PI3K inhibition, classical
chemotherapeutic agents perturbing microtubule dynamics cause
mitotic arrest and cytotoxicity7. BKM120 is a potent PI3K
inhibitor, but has been reported to also act as a microtubule-
destabilizing agent (MDA). In spite of this ﬁnding, it has been
claimed that there is a therapeutic window where BKM120 targets
PI3K selectively without any interference with microtubule
polymerization8. This conclusion was reached, however, without
a deﬁned binding site for BKM120 on tubulin and an established
molecular mechanism of action of microtubule disruption, and
was additionally based on an incomplete understanding of the
interaction of BKM120 with PI3K.
BKM120 can thus principally act as a PI3K inhibitor or as
a chemotherapeutic agent and its dominant antitumorigenic
action needs to be carefully evaluated to avoid misinterpretation
of preclinical and clinical data. The convoluted mode of action
of BKM120 also compromises the evaluation of biomarkers, and
a rational set-up and evaluation of drug combination therapies.
If one attributes BKM120’s antiproliferative action to PI3K
inhibition, elimination of its MDA activity should be beneﬁcial, as
MDAs often display severe toxic side effects upon prolonged
therapy9. A comprehensive elucidation of the mode of action of
BKM120 is therefore crucial to improve the rationale of clinical
studies involving buparlisib drug combinations, and will also
contribute to the development of next-generation PI3K
inhibitors.
Here, a combination of chemical, structural and biological
approaches was used to dissect the above-mentioned ambiguities
and provide a detailed understanding of the molecular interac-
tions of BKM120 with tubulin and PI3K.
Results
Derivatives of BKM120 deconvolute its MDA and PI3K activity.
As a ﬁrst step we aimed to separate the two biological activities
of BKM120 and to produce related chemical derivatives that
speciﬁcally target either PI3K or tubulin. An important part
of the approach was to retain the drug-like properties of the
parental compound. An exchange of the core pyrimidine with
pyridine produced microtubule targeting drug 147 (MTD147),
a compound with pronounced MDA activity and minimal PI3K
inhibition. Replacing the BKM120 core with triazine yielded
PQR309, which excelled as a potent pan-PI3K inhibitor with
no detectable MDA activity. PI3K activity was monitored by
phosphorylation of PKB/Akt, and phosphorylation of Histone
H3 was used as an indicator of mitotic arrest (Fig. 1a,b,
Supplementary Fig. 1a,b and Supplementary Fig. 1i–m).
In ﬁve reference cancer cell lines (A2058, BT-549, SKOV-3,
U87-MG and HCT116) the established MDAs nocodazole and
colchicine, as well as MTD147 and BKM120, all triggered Histone
H3 phosphorylation (Supplementary Fig. 1b and Supplementary
Fig. 1i–m), nuclear DNA condensation (Supplementary Fig. 1c
and Supplementary Fig. 1i–m) and the accumulation of cells in
G2/M or sub-G1 fractions. These events are clear evidence of
mitotic arrest or entry into apoptosis (Supplementary Fig. 1e–h).
In contrast, PQR309 and the structurally unrelated pan-PI3K
inhibitor GDC0941 did not display apoptotic activities and
arrested cells in the G1/S phase. Although BKM120 and PQR309
achieved half-maximal growth inhibition at indistinguishable
concentrations at approximately 1mM (Supplementary Fig. 1d
and Supplementary Fig. 1i–m), they clearly showed a different
mode of action. Combined, the above assays indicate that the
MDA activity of BKM120 dominates its biological action.
An enlarged 44-cell line panel monitoring cell viability and
proliferation conﬁrmed the above reference cell line values and
was exploited to collect IC50-independent compound character-
istics: the comparison of cell line drug sensitivity proﬁles revealed
that PQR309 had highest similarity to the PI3K inhibitor
reference compounds GDC0980 and GDC0941, while BKM120
and MTD147 deviated from PI3K-inhibitor sensitivity patterns
(Fig. 1c and Supplementary Tables 1 and 2). This divergence was
reinforced by Hill slope analysis of dose–response curves for cell
viability, which has been used before to distinguish distinct
drug classes10. Hill slopes close to –1 were obtained for PQR309
and the two PI3K-inhibitor controls. BKM120 and MTD147,
however, displayed Hill slope values of o–2 (Fig. 1d,e and
Supplementary Table 3), which were statistically indistinguishable
from Hill slopes obtained with nocodazole and colchicine
(Supplementary Fig. 1n).
Cell line-speciﬁc cross-correlations of Hill slopes for
compound pairs revealed a high similarity of PQR309 with
PI3K inhibitor reference compounds, while BKM120 and
MTD147 displayed an increased variance (Fig. 1f and
Supplementary Fig. 1o). Furthermore, least-square penalty score
calculations for Hill slopes were close to baseline for pairs of
PQR309, GDC0980 and GDC0941, while BKM120 and MTD147
penalties exceeded values of 100 when cross-correlated to any
PI3K inhibitor (Fig. 1g). Finally, and consistent with the cell line
panel analysis, BKM120 and MTD147 elevated the number of
cells positive for phosphorylated Histone H3 in all tested
cell lines, whereas PQR309 reduced the number of phospho-
Histone H3-positive cells in 38 out of 39 cases (Fig. 1h).
The data described above demonstrate that minimal changes in
the pyrimidine core of BKM120 allow a separation of its PI3K
and MDA activities into discrete BKM120 derivatives. The
matching cell cycle arrest phenotypes of BKM120 and MTD147
indicate that BKM120 prevents proliferation by a mitotic block
rather than through inhibition of PI3K.
BKM120 modulates microtubule dynamics in vitro and in cells.
To elucidate whether the mitotic arrest is mediated by a direct
perturbation of microtubule dynamics, we analysed the effects
of the drugs in an in vitro microtubule reconstitution assay and
in stably transfected HeLa cells, both using GFP-tagged EB3 as
a microtubule plus end marker. We found that MTD147
(Z0.5 mM) and BKM120 (Z1 mM), but not PQR309 (5 mM),
attenuated microtubule growth rates and increased catastrophe
frequency in vitro (Fig. 2a–c) and in cells (Fig. 2d–f). As our
results match data previously obtained for MDAs such as
colchicine11, we conclude that BKM120 and MTD147 directly
perturb microtubule dynamics, and that tubulin binding is the
cause of the antiproliferative action of BKM120 and MTD147.
BKM120-binding site and orientation in ab-tubulin. To
provide insights into the mechanism of action of BKM120 and
MTD147, crystal structures of both compounds bound to tubulin
in a complex composed of two ab-tubulin heterodimers (T2), the
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Figure 1 | Splitting BKM120’s inherent biological activities. (a) Exchange of BKM120’s pyrimidine core with pyridine yields MTD147; a triazine core is
present in PQR309. Rectangles below chemical formulas schematically indicate microtubule-destabilizing agent (MDA, red) and PI3K (green) inhibitor
activities. (b) Ratios of cellular MDA activity (EC50 pHistone H3) over PI3K inhibition (IC50 pPKB; compounds colour-coded as in a) were determined for
the indicated cell lines (EC50 of phospho-Histone H3 for PQR309 was set to 20mM due to the absence of response; for values see Supplementary
Materials: Supplementary Fig. 1a,b and Supplementary Fig. 1i–m). PI3K inhibition was assessed by phosphorylation of Akt/PKB (Supplementary Fig. 1a),
MDA activity by high-content microscopy detecting phospho-Histone H3 (Supplementary Fig. 1b) and nuclear DNA condensation (Supplementary Fig. 1c),
and was correlated with proliferation (Supplementary Fig. 1d). (c) Drug sensitivity of 44 cell lines exposed to indicated compounds. Individual IC50s of cell
line growth were related to the mean IC50 of all cells lines, and cell lines were sorted by lowest to highest sensitivity for PQR309 from left to right
(for values and cell lines see Supplementary Tables 1,2; mean of duplicate experiments of a 9-point serial drug dilution for each cell line). (d) Dose–
response curves for cell viability: displayed are of dose–response curves averaged over all 44 cell lines (n¼ 88 (duplicates of 44 cell lines), mean±s.e.m.;
colour code as in c). Hill slopes are indicated as dashed black lines. (e) Hill slope values of individual cell line viability curves (drugs added coloured as in c;
****depict Po0.0001 (Friedmann’s test with Dunn’s multiple comparison) for comparison with PQR309, GDC0980, GDC0941). Indicated values are
mean±s.d. (f) Cross-correlation of cell lines’ Hill slopes of indicated drug pairs. Dashed lines reﬂect the Hill slope ratio of 1 (for more results see
Supplementary Fig. 1o). (g) Cross-correlation penalty score calculations based on Hill Slopes (see Methods). (h) Heat map depicting drug-induced fold
changes of phospho-Histone H3-positive cells 24 h after drug treatment (all compounds at 2 mM; colchicine 200nM) as compared to DMSO. Cell lines are
sorted according to sensitivity to PQR309 (n¼6 for K562 and LS174-T n¼ 3). An overview of chemical formulas of relevant compounds is provided in
Supplementary Fig. 1p. NS, nonsigniﬁcant.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14683 ARTICLE
NATURE COMMUNICATIONS | 8:14683 | DOI: 10.1038/ncomms14683 |www.nature.com/naturecommunications 3
stathmin-like protein RB3 (R) and tubulin tyrosine ligase
(TTL; the complex is denoted T2R-TTL12,13) were determined at
resolutions of 2.05 and 2.25Å, respectively (Supplementary
Table 7), while PQR309 could not be soaked into T2R-TTL
crystals. The tubulin–ligand complex structures revealed that
both compounds bound in an indistinguishable fashion to
the colchicine site14 located between the a- and b-tubulin
subunits (Fig. 3). It is well established that MDAs targeting
this site inhibit the ‘curved-to-straight’ conformational change
that must occur to allow free ‘curved’ tubulin to incorporate
into ‘straight’ microtubules14. Our structural data (Fig. 3) thus
classify BKM120 and MTD147 as colchicine-site MDAs and are
consistent with cell cycle and microtubule dynamics data shown
in Figs 1 and 2, as well as classical microtubule polymerization
assays (Supplementary Fig. 2 and Supplementary Table 4).
Interactions between BKM120 and tubulin are mediated by an
extensive network of direct and water-mediated contacts between
polar and hydrophobic atoms (Fig. 3b). The core pyrimidine ring
nitrogens are, however, devoid of any hydrogen bonding contacts.
Despite its structural similarity to BKM120 and MTD147,
PQR309 does not bind to tubulin. This suggests that the
additional nitrogen in the core triazine of PQR309 is crucial to
prevent its interaction with tubulin. At a resolution around 2Å,
a nitrogen cannot be distinguished from a C–H group in an
aromatic ring and thus generates a pseudo-symmetry in the
BKM120 molecule (Supplementary Fig. 3). This pseudo-symme-
try obscures the deﬁnitive positioning of the core C–H group
towards b-tubulin residues bLeu248 or bMet259 and thus
prevents the full annotation of interactions.
To resolve this ambiguity, we produced asymmetric BKM120
derivatives by replacing each morpholino group with pyrrolidine
to generate the corresponding regioisomers MTD265 and
MTD265-R1 (Fig. 4a and Supplementary Fig. 4a,b). Remarkably,
MTD265 induced mitotic arrest at 30 times lower concentrations
than MTD265-R1 (Fig. 4b). The difference in potency of
MTD265 versus MTD265-R1 as microtubule polymerization
inhibitors could also be conﬁrmed in vitro (Supplementary
Fig. 4c–e and Supplementary Table 4).
Crystal structures of tubulin-MTD265 and tubulin-MTD265-
R1 complexes at resolutions of 2.15 and 2.25Å, respectively
(Supplementary Table 7), clearly resolved that the morpholino
moieties of MTD265 and MTD265-R1 point towards the guanine
nucleotide-binding site, as in the case of BKM120 and MTD147
(Fig. 4c,d and Supplementary Fig. 4a,b). This result, in
combination with the distinct biological activity of the two
MTD265 regioisomers, deﬁnes the high-afﬁnity orientation
of the core pyrimidine with its C–H group pointing towards
bMet259 (C–H in position V, see Fig. 4a). The higher potency of
MTD265 as compared with MTD265-R1 can be explained by
multiple differential contacts: (i) the formation of a favourable
SyH–C aryl interaction15 of MTD265’s pyrimidine C–H group
with the lone pair electrons of the bMet259 sulfur atom and
(ii) hydrophobic interactions with the side chain of bAla316
(Fig. 4c). In MTD265-R1, the core nitrogen in position V points
towards bMet259 and is expected to cause lone pair repulsions
with the bMet259 sulfur atom and the backbone amide of
bAla316.
Finally, the side chain of bLys352 is positioned such that it
permits for a cation interaction between its z-nitrogen atom and
the core p-system16 of BKM120, MTD147 and MTD265 (Fig. 4d).
The relocation of a core nitrogen to position V in MTD265-R1
(Fig. 4a,d) is likely to move electronegativity in the p-system away
from the morpholino group, which might explain why the
bLys352 is poorly resolved in tubulin-MTD265-R1 complex
structures.
Taken together, these data suggest that high afﬁnity binding of
BKM120 to tubulin occurs via the core C–H group oriented
towards bMet259. This conclusion readily explains why PQR309
(Fig. 2a–c and Supplementary Fig. 2a,b) and the BKM120
regioisomer (BKM120-R1; Supplementary Fig. 4g–j) do not
perturb microtubule dynamics, as there is no possible orientation
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Figure 2 | Drug-dependent changes in microtubule dynamics.
(a) Representative kymographs depicting in vitro microtubule dynamics
determined in the presence of the microtubule plus end tracking protein
GFP-EB3 and the indicated drugs. To save space, kymographs were
truncated horizontally to the longest microtubule traces. Time bar
(vertical, 60 s) and distance bar (horizontal, 3mm) apply to all images.
(b) Quantiﬁcation of the in vitro microtubule catastrophe frequency derived
from experiments as exempliﬁed in a in the absence or presence of
indicated drugs (mean±s.d., DMSO n¼ 5, compounds n¼ 3, *P¼0.036,
Mann–Whitney test). (c) Quantiﬁcation of microtubule growth rates in vitro
(mean±s.d., DMSO n¼ 5, compounds n¼ 3, *P¼0.036, Mann–Whitney
test). (d–f) Microtubule dynamics were monitored in HeLa cells stably
expressing plus-end binding EB3-GFP in the presence of PQR309, BKM120
and MTD147 using live cell microscopy and are illustrated as kymographs.
Time bar (vertical, 20 s) and distance bar (horizontal, 3mm) apply to all
images. (e) Quantiﬁcation of cellular microtubule catastrophe frequencies
(mean±s.d. DMSO n¼ 5, PQR309 n¼4, BKM120 and MTD147 n¼ 3;
*P¼0.0238, Mann–Whitney test) in the presence of indicated drugs.
(f) Quantiﬁcation of drug effects on cellular microtubule growth rates
(mean±s.d., DMSO n¼ 5, PQR309 n¼4, BKM120 and MTD147 n¼ 3;
*P¼0.0238, Mann–Whitney test).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14683
4 NATURE COMMUNICATIONS | 8:14683 | DOI: 10.1038/ncomms14683 | www.nature.com/naturecommunications
to prevent repulsive forces between their core nitrogens and
bMet259.
Orientation of BKM120 core nitrogens deﬁne PI3K interaction.
The importance of the BKM120 pyrimidine core orientation for
tubulin binding prompted us to revisit available PI3K-inhibitor
complex structures and to analyse them for structural
ambiguities. A 3.2 Å resolution crystal structure of the PI3Kg
catalytic subunit (p110g) in complex with BKM120 has been
previously reported4. At this resolution a precise positioning of
the BKM120 molecule in the p110g-binding site is not possible.
To validate the rotational orientation of BKM120 in PI3K, the
asymmetrically substituted BKM120 derivatives PIKiN1 and
PIKiN2, as well as their relevant regioisomers PIKiN1-R1 and
PIKiN2-R1, were produced (Fig. 5a,c). To abrogate one of the two
possible hydrogen bonds of BKM120 with the backbone amide of
Val882 (default numbering for p110g; Val851 in p110a), one
morpholino group was substituted by a piperidine, where the
morpholino oxygen was replaced by a –CH2– group. PIKiN1 and
PIKiN1-R1 represent thus the simplest BKM120 derivatives that
produce a functional asymmetry (Fig. 5a). Interestingly, PIKiN1
and PIKiN2 bound to recombinant p110g, p110a, p110b and
p110d with a 7–30-fold higher afﬁnity as compared to their
regioisomers (Fig. 5b,d and Supplementary Table 5), which
was also conﬁrmed in a p110a activity assay measuring
directly PtdIns(3,4,5)P3 (Supplementary Fig. 6 and Suppleme-
ntary Table 6). This difference in activity between regioisomers
was also reﬂected in cellular assays speciﬁcally monitoring
pan-PI3K, PI3Kg and PI3Kd inhibition (6–10-fold; Suppleme-
ntary Fig. 5a–d). Assuming that the piperidine cannot interact
with the backbone amide of Val882 and is pointed towards the
solvent, this result demonstrates that the orientation of the
pyrimidine core has a signiﬁcant impact on PI3K inhibitor
activity.
To clearly determine the orientation of the substituted
morpholino group, a bulky chloromethyl-azetidin-methanol
substitution was introduced: here the orientation of the
pyrimidine core of PIKiN2 bound to p110g could be unambigu-
ously determined in a crystal structure resolved to 2.51Å. Its core
BKM120
GTP
β-tubulin α-tubulin
βL248
K254
αS178
αT179
βM259
βE200βY202
GTP
Mg2+
βH7
βS10 βS8
βT7
αT5
βV238
βA250βC241
αV181
βI378
βI318
βA316
αN101
βL255
βN258
βL248
βK254
αS178
αT179
βM259
βE200βY202
GTP
Mg2+
βH7
βS10 βS8
βT7
αT5
βV238
βA250βC241
αV181
βI378
βI318
βA316
αN101
βL255
βN258
βS10 βS8 βS9
βH7
βT7
βH8
αT5
BKM120
BKM120 MTD147
BKM120
a b
c d
Figure 3 | Interactions of BKM120 and derivatives with tubulin. (a) Backbone of the ab-tubulin heterodimer (in cartoon representation) in complex with
BKM120; GTP is shown in spheres representation (PDB ID 5M7E). (b) BKM120 binding site in tubulin. Relevant amino acids are labelled in single letter
code; secondary structure elements (marine blue) are H: helix; S: b-sheet; T: T-loop, preceeded by the respective tubulin subunit, a or b. Resolved water
molecules are indicated as red spheres; dashed lines denote hydrogen bonds or interactions discussed in the main text. (c) Overlay of BKM120 and
MTD147 (PDB ID 5M7G) binding to the colchicine-binding pocket of tubulin in the T2R-TTL complex. None of the compounds affected the global
conformation of tubulin in the complex (rmsd 0.290Å; 1941 Ca atoms) compared to the non-ligated T2R-TTL complex (PDB ID: 4I55, refs 12,13). Residues
of strands bS8 and bS9, loop bT7 and helices bH7 and bH8 of b-tubulin and of loop aT5 of a-tubulin form the boundaries of the binding site. For all
investigated compounds, the triﬂuoromethyl substituted a-aminopyridine moiety pointed into the hydrophobic pocket outlined by side chains of bCys241,
bLeu248, bAla250, bAla316, bIle318 and bAla354, with its amino group in H-bond distance to the bTyr202 OH and the bVal238 backbone carbonyl. The
ring nitrogen is in H-bond contact to bGlu200 and bTyr202 through a water molecule. One morpholino group points towards the nucleotide-binding site,
with the ether oxygen connected to two water molecules that establish an H-bond network to the side chains of Asn101 of a-tubulin, to Lys254 of b-tubulin,
to the alpha and gamma-phosphates of the nucleotide and to the backbone carbonyl of Ser178 of a-tubulin. (d) Overlay of the BKM120 binding region in
ab-tubulin in the context of a microtubule (‘straight’ tubulin conformation, grey; PDB ID: 1JFF35) and in ab-tubulin bound to BKM120 (orange).
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pyrimidine C–H group points towards Tyr867 (position U in
Fig. 5e and Supplementary Table 8). This result clearly opposes
the crystal structure of the p110g–BKM120 complex previously
reported by Burger et al.4 and models of BKM120–p110a
complexes derived thereof3; all these studies positioned a core
nitrogen towards the tyrosine Tyr867 in p110g.
To test whether the C–H core group oriented towards Tyr867
is required for PI3K inhibition, we produced the BKM120
regioisomer (BKM120-R1; Supplementary Fig. 4g) and PI3KiN3
(Fig. 5c), which always point a core nitrogen towards Tyr867 of
p110g. Both modiﬁcations had little effect on PI3K inhibitor
afﬁnities (Supplementary Table 5, Fig. 5d and Supplementary
Fig. 5e–g), suggesting that the core nitrogens, but not the C–H
group, are required for the interaction with PI3K. This conclusion
is further supported by a 2.48Å resolution p110g–PI3KiN3
complex structure, which displays an identical binding mode for
PI3KiN3 as for PI3KiN2 (Fig. 5f and Supplementary Table 8).
Closer inspection of the p110g–PI3KiN2 and p110g–PI3KiN3
complex structures revealed that (i) the core nitrogen in position
V is hydrogen bonded through a structured water molecule to
Asn951 and Asp964, and (ii) that the triﬂuoromethyl-pyridin-2-
amine group and aspartates 841, 836, 964 coordinate
two additional structured water molecules (best resolved in the
PI3KiN3 complex; Fig. 5e,f). Molecular dynamics simulations
with BKM120 docked into p110g demonstrated that positioning
of the pyrimidine core C–H group towards Tyr867 kept
the structured water network intact (CU–H; Fig. 5g). In
contrast, when BKM120 was oriented as in the initially reported
structure by Burger and colleagues4 (CV–H; Fig. 5h), hydrogen
bond interactions between the inhibitor, water molecules, side
chains of Asp964 and Asp836 were disrupted. These data suggest
that high-afﬁnity PI3K binding of BKM120 and its derivatives
only occurs when a core nitrogen (in the V position) interacts
with a structured water molecule, which readily explains
why MTD147 without a suitable core nitrogen loses potency as
a PI3K inhibitor.
Clinical BKM120 levels—relation to biological action. The
separation of BKM120’s activities into the PI3K inhibitor PQR309
and the MDA MTD147 allows a deeper analysis of the drug’s
effects at therapeutically relevant concentrations. With PQR309,
PI3K inhibition of 87–95% is required to inhibit proliferation by
50% in most cell lines. For MTD147, the same effect is achieved
with as little as 13–28% of the maximal achievable Histone
H3 phosphorylation (Fig. 6a,b), which is in agreement with
ﬁndings that cytotoxicity is already caused when 2–20% of the
total tubulin pool is bound to microtubule-binding compounds17.
BKM120 yielded 87–95% PI3K inhibition at 1.4±0.8 mM, while
the required concentration to reach 13–28% of MDA activity was
0.8±0.2 mM. Both values are close to the observed IC50 for
proliferation reached at 0.9±0.2 mM (Supplementary Fig. 1d),
thus leaving no window for selective PI3K inhibition. Similarly,
a concentration of 1.2 mM BKM120 is required for median
half-maximal inhibition of proliferation of 44 different cell lines
(see Fig. 1 and Supplementary Table 2). These values match
previously published data for 282 cells lines or primary cells.
Seventy-ﬁve per cent of all cell lines in each panel have an
IC50Z0.9 and 0.75 mM, respectively (Fig. 6d). This illustrates that
most cell lines only show signiﬁcantly attenuated proliferation at
BKM120 concentrations where the drug affects microtubule
dynamics.
In patients, mean BKM120 plasma concentrations range from
1.5 to 2mM at 50mg per daily dosing (q.d.) and 2–3 mM at 100mg
q.d. as calculated from published values (area under the curve,
AUC0–24h; refs 6,18). These drug levels strongly suggest that
BKM120 also targets microtubules dynamics during therapy
(Fig. 6c) and that on/off-target activities cannot be selectively
controlled.
Discussion
BKM120 has excellent pharmacological properties, is highly
selective for the class I PI3K family versus protein kinases and is
one of the few PI3K inhibitors that readily crosses the blood brain
barrier3–6. This provides additional therapeutic opportunities to
target malignant cells in the brain, but exposes this organ to
BKM120 off-target actions. Dose-limiting toxicities caused by
MDAs in the brain are difﬁcult to evaluate in animal models7,
a fact that emphasizes the importance of an exact understanding
of molecular mechanisms of drug actions.
We succeeded in separating the activities of BKM120 as a PI3K
inhibitor and an MDA by minimal chemical modiﬁcation of its
core pyrimidine ring. The resulting selective PI3K inhibitor
PQR309 and the MDA MTD147 thus allowed a proﬁling
of BKM120 against the closest possible reference compounds.
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Figure 4 | Determination of core pyrimidine orientation in tubulin
complexes. (a) Chemical formulas and schematic orientation of BKM120
regioisomeric derivatives MTD265 (PDB ID 5M8G) and MTD265-R1
(PDB ID 5M8D) in tubulin. (b) Phospho-Histone H3-positive A2058 cells
triggered by increasing concentrations of MTD265 (grey) or MTD265-R1
(blue; % of total cells, n¼ 3, mean±s.e.m.). (c,d) Structural overlay of
amino acid side chains relevant for pyrimidine core ring interactions with
BKM120 (orange), MTD147 (red), MTD265 (grey) and MTD-265-R1
(sky blue) in stick representation. The indicated water molecule is oriented
towards the GTP-binding site (c) Visualization of bMet259 and bAla316
interactions with the pyrimidine core of MTD265 and MTD-265-R1
(core C–H protons shown in black). (d) bLys352 cation in proximity to
pyrimidine core p-system of MTD265 and MTD-265-R1. The bLys352 side
chain is fully resolved in crystal structures of BKM120, MTD265 and
MTD147, but is poorly deﬁned in MTD265-R1 complex beyond the dCH2 of
bLys352 (yellow spheres and cloud denote poorly deﬁned atoms).
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The analysis of cancer cell line sensitivity and cell cycle proﬁles,
hill slopes of dose–response curves, PI3K and MDA activities
all revealed that the cellular activity of BKM120 matches the
mode of action of MTD147 and known microtubule disruptors
such as nocodazole and colchicine. This similarity of BKM120 to
other MDAs connects its dominant cellular action with a mitotic
arrest by directly interacting with tubulin dimers to perturb
microtubule dynamics.
Our structural analysis of the BKM120–tubulin interaction
elucidates how the orientation of the BKM120 molecule within its
binding site is governed by hydrophobic interactions, and
illustrates that a rotation of BKM120 by 180 switches between
a high- and a low-afﬁnity conformation as corroborated by the
structures and activities of MTD265 and MTD265-R1. Interestingly,
the same is true for PI3K: here a water network stabilizes
inhibitor contacts with evolutionarily conserved amino acid side
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Figure 5 | Binding of asymmetric BKM120 derivatives to PI3Ks. (a,c) Chemical formulas of regioisomeric pairs. Val882 and Tyr867 of p110g
indicate schematically the drugs orientations. (b,d) PI3K isoform-speciﬁc competitive binding assays used for Kd calculations in Supplementary Table 4
(nZ2 2 (details in Methods); error bars omitted when smaller than symbols). (e,f) Co-crystal structure of p110g soaked with PIKiN2 (e, (PDB ID 5JHA))
and PIKiN3 (f, (PDB ID 5JHB)), depicting structured water molecules (red numbered spheres), and water coordinating amino acids with hydrogen bonds as
dashed lines. (g,h) Two opposing orientations of BKM120 in p110g were set as starting points for modelling of water movements. Positions of water dipoles
after molecular dynamics calculations and energy minimization are shown. The BKM120 structure (from PDB ID 3SD5) was ﬁtted into the protein/water
scaffold of the PIKiN3–p110g complex before molecular dynamics calculations. Water molecules, but not BKM120 and protein, were allowed to move during
calculations.
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chains, which include the ATP-binding DFG motif. Structured
water is present in other PI3K and protein kinase structures, but
was rarely considered in rational drug design. Mutations affecting
water networks might, however, contribute to loss of drug action,
as it has been recently observed for the BCR-Abl inhibitor
bosutinib: in this case, water-mediated hydrogen bonds at the
DFG motif of the kinase were reported to determine drug
selectivity and resistance19.
The precise structural and chemical dissection of the drug’s
dual activity allowed a reassessment of the respective target
occupancy required to inhibit cell proliferation: the availability
of MTD147 and PQR309 shows that cellular phenotypes
associated with disruption of microtubule dynamics require low
EC values, while PI3K needs to be inhibited 490% to achieve
a 50% inhibition of cell proliferation. In this context, our results
strongly suggest that BKM120 blocks cell proliferation mainly via
microtubule disruption and not through PI3K inhibition.
BKM120 plasma concentrations in patients undergoing
continuous dosing have been reported by Bendell et al.18 and
Saura et al.6 and exceed levels required to trigger MDA activity.
One might therefore expect that BKM120 concentrations at
steady state in repetitive daily dosing protocols effect microtubule
dynamics, and that these contribute to antitumour activity and
adverse effects of the drug.
It remains presently elusive if the mixed PI3K/MDA proﬁle of
BKM120 is preferable over a pure PI3K inhibitor in clinical
settings. Indeed, a variety of ongoing clinical trials already test
combinations of PI3K and microtubule inhibitors for efﬁcacy in
cancer treatment (clinicaltrials.gov). Current treatment schemes
involve dosing of microtubule-targeting drugs such as Paclitaxel
at 1–3 week intervals, while PI3K inhibitors are applied on a daily
basis. Our studies have shown how the bipartite activities of
BKM120 can be separated and can provide ﬂexible dosing
schemes: the process has produced PQR309, a speciﬁc PI3K
inhibitor devoid of MDA activity, which is now in phase II
clinical trials. The highly potent MDA MTD265 demonstrates
that BKM120 can serve as a seed molecule for novel colchicine-
site binding MDAs.
In clinical settings where combined targeting of PI3K and
microtubule dynamics proves to be beneﬁcial, distinct PI3K
inhibitors and MDAs provide ﬂexibility in drug scheduling
schemes. Furthermore, in such a setting speciﬁc drug-associated
toxicities and adverse effects can be managed individually
for each target. If united in one drug, dose adaptations of
BKM120 would keep PI3K/MDA activity ratios on a linear
trajectory without the possibility to control target saturation
individually. This means that once a maximally tolerated dose is
reached for one target, a full therapeutic access to the second
mode of action is limited by the target with the lower maximally
tolerated dose (Fig. 7).
PI3K inhibitors and MDAs target similar processes associated
with tumour promotion, such as tumour cell growth and
proliferation, but they also affect endothelial function and
angiogenesis. As the molecular mechanisms to achieve these
therapeutic effects are unrelated, beneﬁcial synergisms and
suppression of drug resistance are the motivation of current
combinatorial drug trials.
In a randomized double-blind study (BELLE-4) BKM120/
buparlisib has been combined with paclitaxel in human epidermal
growth factor receptor 2-negative (HER2) breast cancer patients.
The interim analysis of progression-free survival (PFS) data
of paclitaxel/buparlisib versus paclitaxel/placebo in this phase
II/III study did not warrant the extension into phase III20.
Buparlisib has previously shown encouraging clinical activity
as a single agent21. In the BELLE-4 study, the paclitaxel/buparlisib
combination also failed to show an increase in progression-free
survival in patients with an activated PI3K pathway. Although
it is tempting to speculate that this outcome is linked to the
action of buparlisib as an MDA, dosing schedules, pharmaco-
logical parameters, patient selection, etc. could dominate the
negative clinical outcome. This seems currently to be in
agreement with the phase II PEGGY-study in HER2– patients,
where paclitaxel was combined with the non-brain penetrable
pan-PI3K inhibitor pictilisib (GDC-0941) or placebo, and also did
not reveal a signiﬁcant beneﬁt of the combinatorial treatment22.
The active molecules in the BELLE-4 and PEGGY-study are,
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Figure 6 | BKM120 and derivative drug actions at therapeutic doses.
(a) Plot of MTD147, BKM120 and PQR309 concentrations versus Histone
H3 phosphorylation (% of maximal; red curves), proliferation (black) and
PKB/Akt phosphorylation (pPKB, % of total; green). pHistone H3
phosphorylation and pPKB/Akt levels matching 50% growth inhibition are
indicated by arrows. (b) Levels of phospho-Histone H3 for MTD147 and
% of inhibition of pPKB/Akt for PQR309 correlating with 50% growth
inhibition are shown as mean of A2058, SKOV3, BT549 and U87-MG cells
responses. (c) Calculated concentrations of BKM120 required to achieve
50% growth when associated with either phospho-Histone H3 (red) or
PI3K inhibition (green). The determined IC50 for proliferation for BKM120 is
shown in grey. Shaded areas indicate patient BKM120 plasma levels
reported in ref. 6. Colour code: blue is 50mg per daily (light: after day 8 of
cycle 1; dark: after day 1 in cycle 2); magenta is 100mg per daily (light: after
day 8 of cycle 1; dark: after day 1 in cycle 2). Box and whiskers; whiskers min
to max. (d) Frequency distribution of BKM120’s half maximal concentration
for proliferation per cell viability in the 44 cell lines (top: ﬁrst bin centre
0.1mM, last bin centre 12.1mM, bin width 0.05mM). Bottom: Meta-analysis
of reported BKM120’s IC50 concentrations (mM) for proliferation/cell
viability of 282 cell lines or primary cells, illustrated as frequency
distribution (ﬁrst bin centre 0.01mM, last bin centre 20.01mM, bin width
0.05mM). $ indicates bins containing values that were reported in literature
as IC504x mM (x¼ position of indicated bin). Values were extracted from
refs 36–47.
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however, structurally unrelated and have different physico-
chemical properties. While there are a number of multi-
targeted drugs on the market, advanced clinical studies with
structurally closely related, functionally redeﬁned derivatives are
not available. It will be interesting to follow the progression of
BKM120 and PQR309 through clinical development analysing
differential responses and adverse effects.
Methods
Cell culture. A2058, SKOV3, BT-549, U87-MG and HCT-116 cells
(originating from ATCC) were grown in complete Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (DMEM supplemented with 10% heat-inactivated fetal calf
serum, 2mM L-glutamine and 1% penicillin–streptomycin; Sigma) at 37 C,
5% CO2. Cell lines were tested negative for mycoplasma. Cell line identity was
conﬁrmed using highly polymorphic short tandem repeat loci (STRs) proﬁling
(Microsynth, Switzerland). Bone marrow-derived mast cells (BMMCs) were
isolated, differentiated and grown slightly modiﬁed from ref. 23. In short, cells from
fresh murine bone marrow were suspended in complete Iscove’s modiﬁed
Dulbecco’s medium (IMDM) with 10% heat-inactivated fetal calf serum, 2mM,
L-glutamine, 1% penicillin–streptomycin solution, 50 mM b-mercaptoethanol and
recombinant murine IL-3 (2 ngml 1; Peprotech) and recombinant murine stem
cell factor (5 ngml 1; Peprotech), and cultured at 37 C and 5% CO2 for 4 days.
Subsequently, BMMCs were diluted weekly to 0.5 106 cells per ml with
a mixture of 80% fresh, complete IMDM and 20% recycled medium, with IL-3
added every 2–3 days. Differentiation was monitored by detection of FceRI
(with a phycoerythrin-conjugated hamster antibody to mouse FceRIa; clone
MAR-1; eBioscience #12-5898-83) and c-kit (with a Allophycocyanin-conjugated
anti-mouse CD117/c-kit antibody; clone 2B8; Biolegend #105812) by ﬂuorescence-
activated cell sorting analysis.
In-cell western detection of phosphorylated PKB/Akt. 2 104 cells per well
were seeded in 96-well plates (Cell Carrier; Perkin Elmer) the day before
inhibitor treatment. Inhibitors (or dimethyl sulfoxide (DMSO)) were added for 1 h
(37 C, 5% CO2) at indicated concentrations. Subsequently cells were ﬁxed in
paraformaldehyde (PFA; 4%) in phosphate-buffered saline (PBS) for 30min at
room temperature (RT), and then blocked with 1% bovine serum albumin
(BSA)/0.1% Triton X-100/5% goat serum in PBS (30min, RT). Primary antibodies
(rabbit anti-phospho-Ser473 of PKB/Akt from Cell Signaling Technology # 4058;
mouse anti-a-tubulin, Sigma # T9026; diluted 1:500 and 1:2,000, respectively) were
added overnight (4 C, shaking). The next day, three wash cycles of 5min with
1% BSA/0.1% Triton X-100 in PBS were followed by incubation with IRDye680-
conjugated goat anti-mouse, and IRDye800-conjugated goat anti-rabbit antibodies
for 1 h (LICOR # 926-68070 and # 926-32211, shaking, RT, in the dark), and later
washed 5 5min with 1% BSA/0.1% Triton X-100 in PBS. Fluorescence was
measured with an Odyssey infrared imaging scanner (LICOR; on ‘In Cell Western’
mode, offset 4.0 mm, automatic exposure for both channels, using Image Studio
Ver4.0 software from LICOR). Cells exposed to DMSO represent 100% controls,
and wells without primary antibody are deﬁned as signal background. Percentage
of remaining phospho-Ser473 PKB signal was calculated including a correction
for cellular protein, as determined by tubulin staining. Values were displayed
as a function of inhibitor concentration (log scale) using GraphPad Prism.
IC50 values of inhibitors were determined by ﬁtting with GraphPad’s normalized
nonlinear regression curve function with variable slope:
y ¼ 100= 1þ 10 Log IC50  Log xð ÞHillSlope½ 
 
; where x¼ drug concentration
Data were assessed for A2058, BT-549 in 5, for HCT116 in 4, and for SKOV3 and
U87-MG cell lines in three independent experiments.
High-content/high-throughput microscopy. Cell preparation. A2058, SKOV3,
BT-549, U87-MG and HCT-116 cells were seeded in 100 ml complete DMEM into
96-well plates (Cell Carrier; Perkin Elmer) the day before inhibitor treatment.
Cells were exposed to inhibitors (ranging from 10–0.01 mM, for colchicine and
nocodazole: 1–0.001 mM) for indicated times, and ﬁxed by addition of half a
volume 10% PFA in PBS (30min, RT). Cells were permeabilized and stained with
Hoechst33324 by addition of 1:10 volume of 1% BSA/1% Triton X-100, 22 mM
Hoechst33324 in PBS (30min, RT), followed by a ﬁrst image acquisition, see below.
Subsequently cells were stained overnight (4 C, on a shaker) with rabbit
anti-phospho-serine 10 Histone H3 (Cell Signaling Technologies, # 9701) and rat
anti-a-tubulin antibodies (Clone YL1/2; Santa Cruz Technologies, # sc-53029).
Cells were then washed and incubated with Alexa488-conjugated goat anti-rat IgG,
Alexa647-conjugated goat anti-rabbit IgG antibodies (Life Technologies # A-11006
and # A-21245) and 2.2 mM Hoechst33324 in 1% BSA/0.1% Triton X-100/PBS
(shaking; RT; dark), followed by three wash cycles and a second round of imaging.
Image acquisition. Fluorescent microscopy images were acquired on an
Operetta high content analysis system (Perkin Elmer). Thirty-ﬁve ﬁelds of
view/well were acquired either in confocal mode (z-stacks,  20 high NA
objective, applied in early experiments) or alternatively as wide ﬁeld images
(20x WD objective). 1st acquisition: Nuclear DNA content and DNA morphology
were imaged using the DAPI ﬁlter set. 2nd acquisition: Nuclear DNA,
phosphorylated Histone H3 and a-tubulin images were acquired using DAPI,
Alexa488 and Alexa647 ﬁlter sets.
Image analysis. Images were batch analysed using Columbus software
(PerkinElmer). In case of confocal acquisitions, z-stacks were combined by
maximum projection. Analyses were run including single-cell analysis mode. The
total number of nuclei was determined in the DAPI channel. Nuclear DNA was
classiﬁed into ‘normal’ or ‘condensed’ using a linear classiﬁer mode. The
percentage of cells with condensed DNA was calculated for each well with
% condensed ¼ # cells with condensedDNA= # total cellsð Þ100Þ;
where # is ‘number of ’
Hoechst33324 intensity of each nucleus was further used to calculate cell cycle
distribution in each well using R script.
The fraction of cells with phospho-Histone H3-positive nuclei was determined
using Hoechst33342 and Alexa647 signals. Nuclei were ﬁrst stained for DNA as
described above (Hoechst33342), and nuclei at image borders were excluded
from calculations. The remaining nuclei were classiﬁed as positive or negative for
phospho-Histone H3 by a two-step selection using the ‘ﬁlter by properties’ mode
based on Alexa647 intensities. Alexa647 ﬁlter properties were (i) mean intensities
above threshold/nucleus and (ii) a maximum intensity above threshold. Calculation
was performed with the formula:
% Alexa647positive ¼ #Alexa647positive= # selected nuclei 100;
where # is ‘number of ’
The percentage of cells with condensed DNA, the percentage of phospho-Histone
H3-positive nuclei and the total number of nuclei (normalized to DMSO control as
a measure for proliferation inhibition at 72 h) were plotted as a function of
inhibitor concentration (log scale) using GraphPad Prism. EC50/IC50 values of
inhibitors were determined using GraphPad’s ‘non-linear regression with variable
slope’ formula:
y¼ bottomþ top bottomð Þ= 1þ 10 Log EC50  Log xð ÞHillSlope½ 
 
:
Ratio of mitotic arrest and PI3K inhibition. Concentrations of half-maximal
pSer473 PKB inhibition was determined as described under ‘In Cell Western’.
Half-maximal effective concentrations for appearance of phospho-Histone H3-
positive cells were determined as described under ‘high-throughput microscopy’.
Five cell lines (A2058, BT549, SKOV3, U87-MG and HCT116) were subjected to
both analyses in at least three independent experiments. Subsequently, the ratios of
the mean EC50 for phospho-Histone H3 to the mean IC50 for pSer473 PKB for each
cell line and drug (PQR309, BKM120, MTD147) were calculated. For PQR309 the
EC50 pHistone H3 was set constant to 20 mM, since no increase in mitotic cell
population was detectable with PQR309.
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Figure 7 | Schematic activity map of BKM120 and BKM120 derivatives
and dosing schemes. (a) BKM120 targets PI3K and tubulin proportionally.
A concentration increase of BKM120 does therefore not change
PI3K/tubulin targeting ratios, while combinations of selective PI3K
inhibitors (such as PQR309) and potent microtubule-targeting drugs
(MTDs) allow a ﬂexible access to PI3K inhibition and perturbation of
microtubule dynamics. (b) PI3K inhibitors are typically administered daily
(dosing schedule in green), while microtubule targeting drugs are usually
given in 1–3 week intervals (dosing schedule in red) for a limited time only.
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Viability studies on 44 cell lines. Compound preparation. Compounds were
weighed on a calibrated balance and dissolved in 100% DMSO. DMSO samples
were stored at room temperature. At the day of the experiment, the compound
stock was diluted in 3.16-fold steps in 100% DMSO to obtain a 9-point dilution
series. This was further diluted 31.6 times in 20mM sterile Hepes buffer pH 7.4.
A volume of 5 ml was transferred to the cells to generate a test concentration range
from 3.16 10 5 to 3.16 10 9 M in duplicate. The ﬁnal DMSO concentration
during incubation was 0.4% in all wells.
Cell proliferation assay. The 44 cell lines have been authenticated at the
American Type Culture Collection (ATCC) and have been licensed by NTRC
(Netherlands). Of the 44 cell lines in this commercial cell panel only BT-20 and J82
are listed by the International Cell Line Authentication Committee as eventually
misidentiﬁed. Cell lines were used for experiments below nine cell passages. Assay
stocks of 44 cell lines were thawed and diluted in its ATCC recommended
medium and dispensed in a 384-well plate, depending on the cell line used, at
a concentration of 400–1,600 cells per well in 45 ml medium. The margins of the
plate were ﬁlled with PBS. Plated cells were incubated in a humidiﬁed atmosphere
of 5% CO2 at 37 C. After 24 h, 5 ml of compound dilution was added and plates
were further incubated for another 72 h. After 72 h, 25 ml of ATPlite 1Step
(PerkinElmer) solution was added to each well, and subsequently shaken for 2min.
After 10min of incubation in the dark, the luminescence was recorded on an
Envision multimode reader (PerkinElmer).
Controls. T¼ 0 signal. On a parallel plate, 45 ml cells were dispensed and
incubated in a humidiﬁed atmosphere of 5% CO2 at 37 C. After 24 h 5 ml DMSO-
containing Hepes buffer and 25 ml ATPlite 1Step solution were mixed, and
luminescence measured after 10min incubation (¼ luminescencet¼ 0).
Reference compound. The IC50 of the reference compound doxorubicin is
measured on a separate plate. The IC50 is trended. If the IC50 is out of speciﬁcation
(0.32–3.16 times deviating from historic average) the assay is invalidated.
Cell growth control. The cellular doubling times of all cell lines are calculated
from the t¼ 0 h and t¼ 72 h growth signals of the untreated cells. If the doubling
time is out of speciﬁcation (0.5–2.0 times deviating from historic average) the assay
is invalidated.
Maximum signals. For each cell line, the maximum luminescence was recorded
after incubation for 72 h without compound in the presence of 0.4% DMSO
(¼ luminescenceuntreated,t¼ 72h).
Data analysis. IC50s were calculated by nonlinear regression using IDBS XLﬁt 5.
The percentage growth after 72 h (%-growth) was normalized as follows: 100%
 (luminescencet¼ 72h/luminescenceuntreated,t¼ 72h). This was ﬁtted a 4-parameter
logistics curve:
%-growth¼ bottomþ (top bottom)/(1þ 10[(Log IC50 Log x)HillSlope]),
where bottom and top are the asymptotic minimum and maximum cell growth
that the compound allows in that assay.
Hill slope determination and penalty score calculations. Hill slope steepness was
calculated for (i) drug-concentration-dependent cell viability curves measured at
NTRC (44 cell lines, 72 h) and for (ii) drug-concentration-dependent cell numbers
after 72 h using high-throughput microscopy (A2058, SKOV3, BT-549, U87-MG
and HCT-116 cells). Hill slope steepness for each drug and cell line was determined
by ﬁtting a nonlinear regression curve with variable slope to the data using the
GraphPad Prism function, with x as variable drug concentration:
y¼ bottomþ top  bottomð Þ= 1þ 10 Log IC50  Log xð ÞHillSlope½ 
 
Cell lines (in i) or experiments in (ii) showing for at least one drug high
uncertainty of slope steepness (deﬁned by GraphPad Prism as ‘ambiguous’) were
excluded from analysis.
Statistical analysis of the 36 remaining cell lines from NTRC was performed
using Friedmann’s test with Dunn’s multiple comparison (because normal
distribution was tested negative by D’Agostino-Pearson omnibus normality test for
at least one compound). Statistics for the ﬁve cell lines with at least two
independent experiments for cell number determination were calculated by one-
way ANOVA with Tukey’s multiple comparison tests (normal distribution tested
by D’Agostino-Pearson omnibus normality test).
Penalty scores: penalty scores for cross-correlation of drug pairs are depicted as
sums of individual penalty scores of all 36 included cell lines. For each individual
cell line and drug pair penalty scores (ps) were calculated using
ps ¼ 2 HillSlopedrug1 HillSlopedrug2
 2
Histone H3 phosphorylation in 44 cell lines. Indicated cell lines were cultured in
384-well plates (CellCarrier Ultra) for 18 h in ATCC-recommended media, and
then exposed to 2 mM PQR309, BKM120, MTD147, GDC0941, GDC0980 and
200 nM colchicine for 24 h (37 C, 5% CO2) at NTRC (Netherlands). Cells were
ﬁxed by addition of 10% PFA/PBS (ﬁnal PFA concentration 3.3%). Plates were
subsequently stained for phospho-Ser10 of Histone H3, a-tubulin and DNA
content, and analysed as described under high throughput microscopy (n¼ 6; for
K562 and LS174-T n¼ 3). Cell lines growing loosely adherent or in suspension
(CCRF-CEM, Jurkat-E6-1, MOLT4, SHP-77) were excluded from the analysis.
In vitro microtubule plus end tracking assay. Reconstitution of plus end tracking
in vitro was performed as described previously24. Short microtubule seeds were
prepared by incubating the tubulin mix containing 70% unlabeled porcine brain
tubulin (Cytoskeleton), 17% biotin-tubulin (Cytoskeleton), 6% rhodamine-tubulin
(Cytoskeleton) with 1mM GMPCPP (Jena Biosciences) at 37 C for 30min.
Microtubules were depolymerized on ice for 30min and repolymerized at
37 C with 1mM GMPCPP. The seeds were diluted 10-fold in assay buffer
(80mM Pipes, 4mM MgCl2, 1mM EGTA, pH adjusted to 6.8 with KOH)
containing 10% glycerol, snap frozen in liquid nitrogen and stored at  80 C.
For the reconstitution assay, ﬂow chambers were incubated ﬁrst with
0.2mgml 1 PLL-PEG-biotin (Susos AG, Switzerland), washed with the assay
buffer and then incubated with 1mgml 1 neutravidin. Immobilized seeds were
attached to functionalized glass coverslips by biotin-neutravidin links. Flow
chambers were further incubated with 1mgml 1 k-casein to prevent non-speciﬁc
protein binding. The reaction mix of drugs, assay buffer supplemented with 15 mM
porcine brain tubulin, 50mM KCl, 1mM GTP, 0.2mgml 1 k-casein, 0.1%
methylcellulose and oxygen scavenger mix (50mM glucose, 400 mgml 1 glucose
oxidase, 200mgml 1 catalase and 4mM DTT) was added to the ﬂow chamber.
Experiments were carried out in the presence of 100 nM GFP-EB3. Time-lapse
images of microtubule dynamics were acquired at 30 C using TIRF microscopy.
Live cell imaging (37 C) was performed on a Nikon Eclipse Ti-E microscope
with the perfect focus system (Nikon), equipped with Nikon CFI Apo TIRF 100x
1.49 NA oil objective (Nikon), Photometrics Evolve 512 EMCCD (Roper Scientiﬁc)
and CoolSNAP HQ2 CCD camera (Roper Scientiﬁc), and controlled with
MetaMorph 7.7.5 software (Molecular Devices). A stage top incubator
(INUBG2E-ZILCS; Tokai Hit) controlled temperature.
Analysis of microtubule plus end dynamics in vitro. Maximum intensity
projections and kymographs were made using Metamorph. Microtubule dynamics
parameters were determined from kymographs using the JAVA plug in for
Image J described previously24,25. Each kymograph was split into alternating
phases of growth or shortening. Growth of a microtubule starting from the seed
until the catastrophe was considered as a single growth event, and the rate, time
and length of each event were calculated. The length and the duration of each
phase were measured as horizontal and vertical distances on the kymograph,
respectively. The average velocity was calculated as a ratio of these values.
Catastrophe frequency was calculated as the inverse growth time. The rescue
frequency was calculated by dividing the number of observed rescues by the total
shortening time. Only events with clearly observed start and end were taken into
consideration during the analysis. Growth events shorter than 0.5 mm were not
included in the analysis.
Analysis of microtubule plus end dynamics in HeLa cells. HeLa cells stably
expressing EB3-GFP26 were grown on coverslips for 16 h. Cells were treated with
different drug concentrations and imaged at 0.5 s per frame in stream acquisition
mode using the same TIRF microscope, 30min after drug addition. The TIRF
microscope was used in a semi-TIRF mode which allowed optimal visualization of
the B0.5–1-mm-thick part of the cell proximal to the coverslip. Microtubule
dynamic parameters were measured from kymographs made using Metamorph.
Dynamic parameters were measured only for MTs in the internal part of the cell
and not at the cell cortex. To measure growth rates, the velocity of microtubule end
displacements longer than 0.5 mm were taken into account. Catastrophe frequency
per minute was calculated by dividing the total number of growth events by the
total growth time in minutes.
Statistical analysis. The growth rate and catastrophe frequency in each
condition was calculated by averaging over all microtubules in a movie for
in vitro and by averaging over all microtubules per cell in case of HeLa cells. The
differences between the microtubule dynamics parameters for control and
conditions with drug treatment in the presence of GFP-EB3 in vitro and in
HeLa cells stably expressing EB3-GFP were compared using a non-parametric
Mann–Whitney test. Analysis was made using the GraphPad Prism version 6.04 for
Windows (GraphPad software, La Jolla, CA, USA). In vitro tracking: DMSO n¼ 5,
each drug n¼ 3; cellular microtubule dynamics: DMSO n¼ 6, PQR309 n¼ 4,
BKM120 and MTD147 n¼ 3.
In vitro tubulin polymerization assay. Cell-free tubulin polymerization assays
were carried out with kit #BK006P from Cytoskeleton (Denver, USA) according to
the manufacturer’s instructions. Ice cold tubulin solution (100 ml, 27.5 mM in
supplied polymerization buffer) was added to pre-heated (37 C) 96-well plates
containing 10 ml of inhibitors dissolved in the same buffer. Tubulin polymerization
was then monitored by turbidity changes at 340 nm (OD340) in a Synergy 4
microplate reader (BioTek Instruments) in 1min intervals for 1 h at 37 C. The
initial absorbance in each well (OD340 at t¼ 0) was set as the background, and was
subtracted from OD340 values of subsequent time points. The resulting DOD340 was
blotted as a function of time. For dose–response analysis, values were normalized
to the maximal change of OD340 (DOD340max) of DMSO control experiments.
IC50 values of inhibitors were determined by ﬁtting with GraphPad’s normalized
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nonlinear regression curve function with variable slope:
y¼ 100= 1þ 10 Log IC50  Log xð ÞHillSlope½ 
 
; where x¼ drug concentration
Statistical signiﬁcance for OD340, MAX was tested using non-parametric
Kruksal–Wallis test (small sample number not allowing to test for Gaussian dis-
tribution using D’Agostino-Pearson omnibus normality test, Supplementary
Fig. 2b).
Preparation of proteins. Bovine brain tubulin prepared according to well-estab-
lished protocols27 was purchased from the Centro de Investigaciones Biolo´gicas
(Microtubule Stabilizing Agents Group, fer@cib.csic.es), CSIC, Madrid, Spain. The
recombinant expression and puriﬁcation of the stathmin-like domain of RB3 and
chicken TTL in bacteria, as well as the reconstitution of the T2R-TTL complex was
performed as described previously12–14. The expression and puriﬁcation of the
PI3Kg catalytic subunit (p110g) was performed as described in previously28.
In vitro PI3K inhibitor binding assay. Dissociation constants (Kd) of
compounds for p110g, a, b, d were determined using LanthaScreen technology
(Life Technologies). First, dissociation constants of Kinase Tracer314
(Kd Tracer, # PV6087) for p110g (13.9 nM), p110a (2.2 nM), p110b (3.5 nM) and
p110d (4.1 nM) were determined following the manufacturer’s instructions.
Recombinant PI3Ks were prepared as 3 concentrated stocks of either
N-terminally His-tagged p110a, p110b and p110d associated with p85a or
His-tagged p110g (15 nM), biotin anti-His6-tag antibody (6 nM, # PV6089) and
LanthaScreen Eu-Streptavidin (6 nM, # PV5899) was prepared in 1 Kinase
Buffer A (50mM HEPES pH 7.5, 10mM MgCl2, 1mM EGTA and 0.01% (v/v)
Brij-35). 3 concentrated AlexaFluor647-labelled Kinase Tracer314 was prepared
in Kinase Buffer A (Tracer314 concentrations for p110g: 75 nM, p110a: 60 nM,
p110b: 75 nM, p110d: 30 nM). Compounds were fourfold serially diluted from
120mM to 460 pM in kinase buffer A. Five microlitres of compound dilutions,
5 ml of 3 kinase/antibody mixture and 5 ml 3 Tracer314 solution were mixed
in a 384-well plate (in duplicate) and incubated for 1 h at room temperature.
Time-resolved FRET was measured with a Synergy 4 multi-mode microplate
reader (Biotek Instruments; settings: 100ms delay, 200ms for data collection with
10 measurements per data point. Emission ﬁlters: 665/8 and 620/10 nm; Excitation
ﬁlter: 340/30 nm; Dichroic mirror 400 nm).
For data analysis, mean background (wells with only kinase buffer A) was
subtracted and the emission ratio was calculated by dividing the signal emitted
at 665 nm from the acceptor (AlexaFluor647-labelled Tracer314) by the signal
emitted at 620 nm from the donor (Eu-labelled antibody). IC50 values were
determined by plotting the remaining emission (in % of DMSO control)
as a function of compound concentration (in logarithmic scale) and by
ﬁtting a normalized sigmoidal dose–response curve with variable slope
(y ¼ 100/(1þ 10[(Log IC50 Log x) HillSlope]))
to the data using GraphPad Prism. Kd was calculated as
Kd ¼ IC50=ð1þ Tracer½ =KdTracerð Þ
Experiments for p110a were repeated in three independent experiments in
duplicate (n¼ 3 2, Fig. 3d n¼ 4 2–3). Inhibitor action on the other PI3K
isoform was tested in two independent experiments in duplicate (n¼ 2 2).
PI3Ka activity determined by PtdIns(3,4,5)P3 production. PI3Ka-derived
PtdIns(3,4,5)P3 was detected using an AlphaScreen assay (K-1300) from Echelon
Biosciences following the manufacturer’s instructions. Inhibitors (stocks at 1.6mM
in DMSO) were diluted 10-fold in 1 KBZ (catalog number K-KBZ; Echelon
Biosciences), followed by 10 steps of a four-fold serial dilution in 1 KBZ buffer
supplemented with 10% DMSO. Recombinant human p110a/p85a PI3Ka complex
(E-2000; Echelon Biosciences) was used, and the assay was set up in the following
order: 2.5 ml of each inhibitor (concentration range of 40–0.00015mM), 5 ml PI3Ka
as supplied, and 2.5 ml 20 mM diC8 PtdIns(4,5)P2 (the short fatty acid chain PI3K
substrate; P-4508; Echelon Biosciences) mixed with 40 mM ATP in 1 KBZ buffer.
The reaction mixtures were incubated for 1 h at room temperature, before
PtdIns(3,4,5)P3 was detected using a AlphaScreen GST detection Kit (PerkinElmer)
according to the supplier’s instructions. Samples were ﬁnally processed on a Fusion
Alpha plate reader (Packard). AlphaScreen signals (relative luminescent units,
RLU) were depicted as a function of drug concentration. IC50 values for PI3Ka
inhibition were determined using GraphPad’s ‘nonlinear regression with variable
slope’ formula:
y¼ bottomþ top  bottomð Þ= 1þ 10 Log EC50  Log xð ÞHillSlope½ 
 
Where not indicated, inhibitor action was determined by duplicates of 10-step
serial dilutions, and by quadruplicates for MTD265, PIKiN1-R1, PIKiN2-R1.
Crystallization, data collection and structure solution. Crystals of T2R-TTL
were grown as described in refs. 12, 13 and soaked overnight (BKM120, MTD147)
or for 2 h (MTD265, MTD265-R1) in reservoir solutions containing 2mM of the
indicated compounds. Crystals were ﬁshed directly from the drop and ﬂash-cooled
in liquid nitrogen. Standard data collection was performed at beamline X06DA at
the Swiss Light Source (Paul Scherrer Institut, Villigen, Switzerland). Images
were indexed and processed using XDS29. The structures were determined by the
difference Fourier method in PHENIX30 using the phases of the T2R-TTL complex
(PDB ID 4I4T) in the absence of ligands and solvent molecules as a starting point
for reﬁnement. The resulting model was further improved through iterative model
rebuilding in Coot31 and reﬁnement in PHENIX30. Non-crystallographic
symmetry restraints were applied in initial reﬁnement stages and then omitted
in the ﬁnal cycles of reﬁnement to account for structural variations between the
non-crystallographic symmetry -related copies of a- and b-tubulin. Translation/
Libration/Screw-reﬁnement was included in the ﬁnal cycles of reﬁnement. Data
collection and reﬁnement statistics are given in Supplementary Table 7.
Figures were prepared using PyMOL (The PyMOL Molecular Graphics System,
Version 1.5.0.5. Schro¨dinger, LLC). Chains in the T2R-TTL complex were deﬁned
as follows: chain A, a1-tubulin; chain B, b1-tubulin; chain C, a2-tubulin; chain D,
b2-tubulin; chain E, RB3; chain F, TTL. Chains A and B were used throughout for
the structural analyses and ﬁgure preparation.
Crystals of PI3Kg were prepared as described in ref. 28. In short, crystals were
grown using sitting-drop vapor diffusion by mixing 1 ml of PI3Kg (4mgml 1) and
1 ml of a reservoir solution (16–17% PEG 4000, 250mM (NH4)2SO4 and 100mM
Tris pH 7.5). Crystal seeds were introduced using the seed bead kit (Hampton
Research). Individual soaking with each inhibitor generated ligand co-crystal
structures. Three stocks of each inhibitor were made at concentrations of 10 mM,
100 mM and 1mM in cryo buffer (23% PEG 4000, 250mM (NH4)2SO4, 100mM
Tris pH 7.5 and 14% glycerol). Crystals were incubated with increasing
concentrations of inhibitors by adding 0.5 ml of inhibitor solution and allowing
them to incubate for 60min. As the last step, 1 ml was taken out of the drop and 1 ml
of 1mM inhibitor in cryo buffer was added and inhibitors were allowed to soak
overnight. After soaking, the crystals were transferred to a fresh drop containing
1mM inhibitor in cryo buffer and then immediately frozen by dunking the crystals
in liquid nitrogen.
Diffraction data for the PI3K crystals were collected at 100 K at beamline I04 of
the Diamond Light Source. Data were processed using XDS29. Phases were initially
obtained by molecular replacement using Phaser32, with the structure of PI3Kg
bound to BKM120 used as the search model (3SD5; ref. 3). Iterative model building
and reﬁnement were performed in COOT31 and phenix.reﬁne30, with a ﬁnal Rwork
of 20.2 and an Rfree of 24.5 for the PI3Kg structure bound to PIKiN2,
and Rwork¼ 23.1 and Rfree¼ 27.7 for the PI3Kg structure bound to PIKiN3.
Reﬁnement was carried out with rigid body reﬁnement followed by Translation/
Libration/Screw B-factor and xyz reﬁnement. The ﬁnal model was veriﬁed in
Molprobity for the absence of both Ramachandran and Rotamer outliers33.
Data collection and reﬁnement statistics are shown in Supplementary Table 8.
BMMC assays. BMMCs were collected by centrifugation (160 g for 3min), washed
and starved in IL-3-free IMDM containing 2% heat-inactivated fetal calf serum,
2mML-glutamine and 1% penicillin–streptomycin for 1 h (0.5–1.0 106 cells per
ml). Subsequently BMMC were treated for 30min (37 C, 5%CO2) with PIKiN1
and PIKiN-R1 serial dilutions or DMSO and then stimulated with 2 mM adenosine
(Ade) or 10 ngml 1 stem cell factor for 2min at 37 C. For western blot analysis,
stimulation of cells was stopped on ice and cells were collected by centrifugation
(16,000 g for 1min at 4 C), washed in 1 PBS and lysed at 1 107 cells per ml in
2 sample buffer (125mM Tris-HCl (pH 6.8), 4% SDS, 10% b-ME, 20% glycerol,
bromphenol blue). Proteins were denatured at 95 C for 7min and subjected to
SDS–polyacrylamide gel electrophoresis (PAGE) and western blotting. Total
PKB/Akt and pSer473 phosphorylated PKB/Akt were detected with speciﬁc
antibodies (both from Cell Signaling Technologies, # 2920 and # 4058) and
respective HRP-coupled secondary antibodies (Sigma # A4416 and # A6154).
Enhanced chemiluminescence signals were detected on a Fusion FX-7 device
(Vilber Lourmat). Signals were quantiﬁed using ImageJ. Phospho-Ser473 PKB
signals were corrected for total PKB and plotted as % of stimulated controls
as a function of drug concentration using GraphPad Prism as described above.
Molecular dynamics calculations. Protein and structured water coordinates were
taken from the PIKiN3-p110g structure, and BKM120 (from PDB ID 3SD5) was
then docked in the two orientations shown in Fig. 3g,h. The two complexes
were then submitted to dynamic/minimization calculations with liberated water
molecules, but ﬁxed ligand and protein coordinates.
All energy calculations and minimizations/dynamics used periodic boundary
conditions and the YAMBER3 force ﬁeld34. The system was then energy-
minimized using steepest descent minimization, in order to remove conformational
stress, followed by a simulated annealing minimization until convergence
(o0.05 kJ per mol per 200 steps). Two independent simulations were run: 1,000 fs
at 1,000 K followed by 1,000 fs at 300K. The complex was then minimized until
convergence. Binding energies were calculated using the YASARA default.
Synthetic chemistry. See Supplementary Methods.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14683 ARTICLE
NATURE COMMUNICATIONS | 8:14683 | DOI: 10.1038/ncomms14683 |www.nature.com/naturecommunications 11
Data availability. The atomic coordinates and structure factors have been
deposited in the Protein Data Bank (www.rcsb.org) under accession codes 5M7E
(T2R-TTL-BKM120), 5M7G (T2R-TTL-MTD147), 5M8G (T2R-TTL-MTD265),
5M8D (T2R-TTL-MTD265-R1), 5JHA (p110g-PIKiN2) and 5JHB
(p110g-PIKiN3). The data that support the ﬁndings of this study are available from
the corresponding author upon request. BKM120 is commercially available from
multiple suppliers. To obtain PQR309 please contact the corresponding author.
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